Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma
Hematology Reports · 15.06.2026 · 18 (3) · 41
DOI: 10.3390/hematolrep18030041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematology Reports, online erschienen am 15.06.2026. Verfasst von Tine Rosenberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Odense University Hospital, Kløvervænget 10, 5000 Odense, Denmark. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Janssen-Cilag, Region of Southern Denmark, Odense University Hospital.
Abstract (Originalsprache)
Objectives
For patients with multiple myeloma (MM), an increasing proportion of treatment is now delivered at home. While this shift offers convenience and supports continuity of care, it also demands new ways to ensure patient safety outside the hospital. Although patients receiving home-based treatment are generally clinically stable, each administration still requires a pre-treatment safety assessment, traditionally performed by telephone. We aimed to evaluate whether digital patient-reported outcomes (PROs) could replace these calls to determine treatment readiness.
Methods
This feasibility study included 30 patients (median age 76 years, 60% male). Prior to each scheduled treatment, patients completed a digital symptom questionnaire. An algorithm stratified patients according to treatment readiness. In total, 233 questionnaires were distributed and 179 completed (completion rate 77%). Healthcare professionals were blinded to PRO data during the study, and PRO-based assessments were compared with standard nurse-led telephone evaluations after study completion.
Results
Digital PRO data reliably identified patients ready for treatment. The algorithm achieved a positive predictive value of 100%, indicating concordance between PRO-based readiness classification and clinical decisions. The negative predictive value was 19%, reflecting that most patients reporting symptoms were ultimately eligible for treatment. Overall, nearly 80% of routine pre-treatment telephone calls could safely be omitted without compromising patient safety.
Conclusions
This study suggests that digital PRO-based symptom reporting may support a reduction in routine pre-treatment telephone assessments for selected patients with MM receiving daratumumab. The approach showed potential for streamlining clinical workflows while maintaining patient safety, although confirmatory studies are needed before implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Odense University Hospital, Kløvervænget 10, 5000 Odense, Denmark.
- Department of Clinical Research, University of Southern Denmark, Campusvej 55, 5230 Odense, Denmark.
- Centre for Innovative Medical Technology, Odense University Hospital, Kløvervænget 30, 5000 Odense, Denmark.
- Research Unit of Oncology, Odense University Hospital, 5000 Odense, Denmark.
ORCID-Profile: Jannie Kirkegaard, Anne Mette Ølholm, Thomas Lund
Förderung
- Janssen-Cilag
- Region of Southern Denmark
- Odense University Hospital
Zitieren
APA
Rosenberg, T., Kirkegaard, J., Gundesen, M. T., Ølholm, A. M., Dieperink, K. B., & Lund, T. (2026). Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma. Hematology Reports, 18(3), 41. https://doi.org/10.3390/hematolrep18030041
Vancouver
Rosenberg T, Kirkegaard J, Gundesen MT, Ølholm AM, Dieperink KB, Lund T. Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma. Hematology Reports. 2026;18(3):41. doi:10.3390/hematolrep18030041
BibTeX
@article{Rosenberg2026,
author = {Rosenberg, Tine and Kirkegaard, Jannie and Gundesen, Michael Tveden and Ølholm, Anne Mette and Dieperink, Karin Brochstedt and Lund, Thomas},
title = {Digital Symptom Reporting for Treatment Readiness Before Daratumumab: A Blinded Prospective Study in Multiple Myeloma},
journal = {Hematology Reports},
year = {2026},
volume = {18},
number = {3},
pages = {41},
doi = {10.3390/hematolrep18030041}
}
EUVIMED